The Pcyt2 + /- mouse model is further relevant to humans because in humans, NASH and a decrease in PE synthesis associate with age [21–23] and similarly, Pcyt2 + /- mice do not clinically manifest symptoms at a young age, but progress to a pathological state as adults. This evidence concerns the gene PCYT2 and metabolic dysfunction-associated steatohepatitis.